This article first appeared on GuruFocus .
Release Date: May 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
cbdMD Inc ( YCBD ) reported a 19% year-over-year increase in net sales, reaching $5.6 million.
-
The company's core business, excluding Bluebird Botanicals, showed significant growth, with the highest quarterly revenue since December 2023.
-
The acquisition of Bluebird Botanicals is expected to become a positive contributor to both revenue and earnings in the third quarter.
-
The company is strategically investing in the CMS Substance Access pathway, which could provide significant long-term opportunities.
-
cbdMD Inc ( YCBD ) has regained full NYSE American continued listing compliance, strengthening its financial position.
Negative Points
-
Gross margin decreased to 58% from 62% in the prior year, primarily due to a shift in revenue mix and increased costs from state-level requirements.
-
The acquisition of Bluebird Botanicals was a drag on earnings in the second quarter due to transition costs and integration expenses.
-
The company reported a loss from operations of approximately $801,000, compared to a loss of $486,000 in the prior-year period.
-
State-level regulatory changes have created ongoing packaging changes, repacking costs, and new testing requirements, impacting operational costs.
-
The company is facing challenges in navigating a dynamic regulatory environment, which includes shifting state restrictions that narrow product sales opportunities.
Q & A Highlights
Q: How much of the 11% organic revenue growth was attributable to the Oasis brand versus the core CBD businesses? A: A reasonable amount of the growth was from the Oasis side of the business, alongside some growth in the core CBD business. (Ronan Kennedy, CEO and CFO)
Q: Will there be more granularity in the financial reports regarding the impact of Oasis, or is it not material yet? A: We have not segregated out that category yet, but will continue to evaluate segmentation as we see continued growth. (Ronan Kennedy, CEO and CFO)
Q: How do you expect to use the balance sheet and liquidity profile to support growth opportunities, given the cash burn in recent quarters? A: We made inventory investments ahead of growth and expect to be more efficient from an inventory standpoint moving forward. We anticipate improved EBITDA and reduced working capital requirements. (Ronan Kennedy, CEO and CFO)
Q: What is the status of the reverse stock split proposal, and what is the timeline for its implementation? A: The reverse stock split is more of a protective measure to react quickly if needed due to market volatility. There is no current plan to execute it, but it remains available as a tool. (Ronan Kennedy, CEO and CFO)
Q: Can you provide an update on realizing supply chain or shared service synergies with Bluebird Botanicals, and will it be accretive in the third quarter? A: We incurred transaction and transition costs but are now fully integrated. We had a strong March and April, realizing synergies and leveraging the product portfolio. We expect Bluebird to contribute positively in the third quarter. (Ronan Kennedy, CEO and CFO)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
